Landscapes / Metabolic

Obesity drug landscape

96 drug programs are in active Phase 2 or later obesity trials. 24 come from China-based sponsors, and 4 are already filed or approved in China. In our test on 6 Nov 2026, Claude with web search found 44% of the programs in active trials.

Updated 6 Nov 2026 Sources: ClinicalTrials.gov, openFDA (updated 6 Nov 2026), company press releases (marked “news”) Download CSV

programs in active trials

300

active Phase 2+ trials (list)

from China-based sponsors

13 Nov

next readout: olatorepatide

Approved 7Filed 3Phase 3 27Phase 2 59

Drug	Company	Mechanism	Phase	Next catalyst	Financing	Source
tirzepatide LY3298176 · Zepbound · Mounjaro	Eli Lilly	GIP / GLP-1	Approved (US)	Nov 2026soon Primary completion, Phase 3	Public LLY	NCT06662383
All active trials in this area: NCT05556512 NCT06037252 NCT06075667 NCT06143956 NCT06439277 NCT06643728 NCT06662383 NCT06857942 NCT06864026 NCT06914895 NCT06937086 NCT06937099 NCT06962280 NCT07247084 NCT07299084 NCT07438444 NCT07803744 NCT07817875 NCT07881432 NCT07881458
mazdutide LY3305677 · IBI362	Eli Lilly · Innovent	GLP-1 / glucagon	Approved (China)news	31 Dec 2026 Primary completion, Phase 3	Public LLY · 1801.HK	NCT06884293
All active trials in this area: NCT06143956 NCT06862908 NCT06884293 NCT06931028 NCT07000955 NCT07255209 NCT07469800
ecnoglutide XW003	Sciwind Biosciences	GLP-1, cAMP-biased	Approved (China)news	5 Jan 2027 Primary completion, Phase 1/2	Private	NCT07243171
All active trials in this area: NCT07073417 NCT07243171 NCT07387094 NCT07434050 NCT07734311 NCT07836270
orforglipron LY3502970 · Foundayo	Eli Lilly	Oral small-molecule GLP-1	Approved (US)	Feb 2027 Primary completion, Phase 3	Public LLY	NCT06672549
All active trials in this area: NCT05869903 NCT06672549 NCT06672939 NCT06948422 NCT06948435 NCT06952530 NCT06972459 NCT06972472 NCT06993792 NCT07153471 NCT07202884 NCT07790861 NCT07794579
semaglutide Wegovy · Ozempic · Rybelsus	Novo Nordisk	GLP-1	Approved (US)	1 Mar 2027 Primary completion, Phase 3	Public NVO	NCT07011667
All active trials in this area: NCT05567796 NCT05726227 NCT06571383 NCT06780449 NCT07010432 NCT07011667 NCT07184086 NCT07225816 NCT07253285 NCT07400107 NCT07527195 NCT07564414 NCT07639021 NCT07668414 NCT07767175 NCT07770841 NCT07845578 NCT07855133 NCT07919405
setmelanotide Imcivree	Rhythm	MC4R agonist	Approved (US)	13 Mar 2027 Primary completion, Phase 3	Public RYTM	NCT06760546
All active trials in this area: NCT05774756 NCT06760546 NCT06772597
Naltrexone-Bupropion Combinationunreviewed	Currax Pharmaceuticals	Not yet classified	Marketed (Phase 4 trial)	Jan 2029 Primary completion, Phase 4	Not yet researched	NCT06098079 1 trial
CagriSema cagrilintide + semaglutide · CagriSema (Cagrilintide B and Semaglutide I)	Novo Nordisk	Amylin + GLP-1	Filed (US)news	Dec 2026news US FDA decision expected in Q4 2026 (company guidance, exact date not public)	Public NVO	NCT07011667
All active trials in this area: NCT07011667 NCT07184086 NCT07564414 NCT07919405
HRS-7535 KAI-7535	Hengrui · Kailera	Oral small-molecule GLP-1	Filed (China)news	Dec 2026 Primary completion, Phase 2	Public · Private 600276.SS	NCT06820099
All active trials in this area: NCT06820099 NCT07497880 NCT07528027
ribupatide HRS9531 · KAI-9531	Hengrui · Kailera	GLP-1 / GIP	Filed (China)news	Dec 2026 Primary completion, Phase 3	Public · Private 600276.SS	NCT06974851
All active trials in this area: NCT06391710 NCT06506175 NCT06974851 NCT06994650 NCT07150962 NCT07284875 NCT07284901 NCT07284979 NCT07285902 NCT07458269 NCT07670884 NCT07709910 NCT07793929
olatorepatide	Regeneron	Incretin peptide	Phase 3	13 Nov 2026soon Primary completion, Phase 2	Public REGN	NCT07431086
All active trials in this area: NCT07431086 NCT07685808 NCT07830329 NCT07896265
retatrutide LY3437943	Eli Lilly	GIP / GLP-1 / glucagon	Phase 3	Nov 2026soon Primary completion, Phase 3	Public LLY	NCT06662383
All active trials in this area: NCT06383390 NCT06662383 NCT06859268 NCT07035093 NCT07232719 NCT07357415
IN-B00009	HK inno.N	Not yet classified	Phase 3	31 Dec 2026 Primary completion, Phase 3	Not yet researched	NCT07192263 1 trial
UBT251	United Laboratories · Novo Nordisk	GLP-1 / GIP / glucagon	Phase 3	14 Jan 2027 Primary completion, Phase 2	Public 3933.HK · NVO	NCT07395687
All active trials in this area: NCT07134335 NCT07395687 NCT07648225 NCT07710729 NCT07710768 NCT07767942 NCT07785934 NCT07806851
maridebart cafraglutide MariTide · AMG 133	Amgen	GLP-1 agonist + GIPR antagonist antibody	Phase 3	21 Jan 2027 Primary completion, Phase 3	Public AMGN	NCT06858839
All active trials in this area: NCT06660173 NCT06858839 NCT06858878 NCT06987695 NCT07037433 NCT07037459 NCT07225686 NCT07226765 NCT07441252 NCT07523711 NCT07575399 NCT07684144 NCT07684235 NCT07832799 NCT07866066 NCT07871409 NCT07908316 NCT07921316
lenbelintide AZD6234	AstraZeneca	Amylin	Phase 3	29 Jan 2027 Primary completion, Phase 1/2	Public AZN	NCT06151964
All active trials in this area: NCT06151964 NCT07013643 NCT07017179 NCT07776509 NCT07784270 NCT07784725 NCT07911514 NCT07922330
HDM1005	Huadong Medicine	GLP-1 / GIP	Phase 3	4 Feb 2027 Primary completion, Phase 2	Public 000963.SZ	NCT07521631
All active trials in this area: NCT06886126 NCT07279194 NCT07502001 NCT07521631 NCT07559240 NCT07787260 NCT07794397 NCT07828197
BGM0504	BrightGene	GLP-1 / GIP	Phase 3	28 Feb 2027 Primary completion, Phase 2	Not yet researched	NCT07658560
All active trials in this area: NCT07658560 NCT07743983
cagrilintide	Novo Nordisk	Amylin	Phase 3	1 Mar 2027 Primary completion, Phase 3	Public NVO	NCT07011667
All active trials in this area: NCT05567796 NCT06780449 NCT07010432 NCT07011667 NCT07184086 NCT07220642 NCT07220759 NCT07253285 NCT07411560 NCT07527195 NCT07557953 NCT07597018 NCT07607587 NCT07745504 NCT07919405
eloralintide LY3841136	Eli Lilly	Amylin	Phase 3	Mar 2027 Primary completion, Phase 2	Public LLY	NCT07215559
All active trials in this area: NCT06143956 NCT07215559 NCT07282600 NCT07321886 NCT07353931 NCT07369011 NCT07392190 NCT07589608 NCT07665879 NCT07738614 NCT07765511 NCT07808060 NCT07881432 NCT07881458 NCT07900633
pitolisant Wakix	Harmony Biosciences	Histamine H3 receptor antagonist / inverse agonist	Phase 3 US-approved for another use	Apr 2027 Primary completion, Phase 3	Public HRMY	NCT06366464
All active trials in this area: NCT06366464 NCT07219485
zovaglutide	QL Biopharm	GLP-1	Phase 3	29 May 2027 Primary completion, Phase 3	Private	NCT07230119
All active trials in this area: NCT07230119 NCT07443059 NCT07812597 NCT07916194
mibavademab	Regeneron	Leptin receptor agonist antibody	Phase 3	18 Jun 2027 Primary completion, Phase 3	Public REGN	NCT07220772 1 trial
bofanglutide GZR18 · bofanglutida	Gan & Lee · Carnot Laboratories	GLP-1, every two weeks	Phase 3	30 Jun 2027 Primary completion, Phase 3	Public · Not yet researched 603087.SS	NCT07150975
All active trials in this area: NCT06728124 NCT06974487 NCT07128888 NCT07141030 NCT07144098 NCT07150975 NCT07292441 NCT07355738 NCT07493057 NCT07501832 NCT07622810
MDR-001	MindRank AI	Oral small-molecule GLP-1	Phase 3	Jun 2027 Primary completion, Phase 3	Private	NCT07274137
All active trials in this area: NCT07110766 NCT07274137
VK2735	Viking	GLP-1 / GIP	Phase 3	1 Jul 2027 Primary completion, Phase 3	Public VKTX	NCT07104383
All active trials in this area: NCT07104383 NCT07104500 NCT07838740 NCT07868835 NCT07868939
DA-302168S	Chengdu DIAO	Oral small-molecule GLP-1	Phase 3	9 Jul 2027 Primary completion, Phase 3	Private	NCT07629544
All active trials in this area: NCT07629544 NCT07877038
berobenatide MET-097i · MET097 · PF-08653944	Pfizer	Long-acting GLP-1	Phase 3	4 Aug 2027 Primary completion, Phase 2	Public PFE	NCT07575932
All active trials in this area: NCT07311850 NCT07400653 NCT07508241 NCT07575932 NCT07595549 NCT07792954 NCT07794761 NCT07794774 NCT07823608 NCT07845500 NCT07845513 NCT07874633 NCT07876531 NCT07881757 NCT07915609 NCT07919678
ALN-CIDEB	Regeneron · Alnylam	CIDEB siRNA	Phase 3	17 Aug 2027 Primary completion, Phase 1/2	Public REGN · ALNY	NCT06836609
All active trials in this area: NCT06836609 NCT07854782
MWN109	Shanghai Minwei	Not yet classified	Phase 3	Sep 2027 Primary completion, Phase 3	Not yet researched	NCT07778693
All active trials in this area: NCT06938269 NCT07778693 NCT07791537 NCT07804797
elecoglipron AZD5004 · ECC5004	AstraZeneca	Oral small-molecule GLP-1	Phase 3	6 Apr 2028 Primary completion, Phase 3	Public AZN	NCT07775404
All active trials in this area: NCT07534592 NCT07667803 NCT07723833 NCT07775404
amycretin NNC0487-0111 · zenagamtide	Novo Nordisk	GLP-1 / amylin, one molecule	Phase 3	6 Jun 2028 Primary completion, Phase 3	Public NVO	NCT07503210
All active trials in this area: NCT07339423 NCT07400107 NCT07481630 NCT07503210 NCT07508020 NCT07509307 NCT07533175 NCT07567001 NCT07571005 NCT07571109 NCT07587710 NCT07668401 NCT07668414 NCT07720271 NCT07757087 NCT07815067 NCT07822061 NCT07855133 NCT07861100 NCT07868354
ASC30	Ascletis	Oral small-molecule GLP-1	Phase 3	Jul 2028 Primary completion, Phase 3	Public 1672.HK	NCT07743450
All active trials in this area: NCT07743450 NCT07743463
aleniglipron GSBR-1290	Structure Therapeutics	Oral small-molecule GLP-1	Phase 3	Sep 2028 Primary completion, Phase 3	Public GPCR	NCT07654361
All active trials in this area: NCT07654361 NCT07654374
HDM1002	Huadong Medicine	Oral small-molecule GLP-1	Phase 3	— No upcoming date in registry	Public 000963.SZ	NCT06885021
All active trials in this area: NCT06885021 NCT07331389
HDM1702	Huadong Medicine	Not yet classified	Phase 3	— No upcoming date in registry	Public 000963.SZ	NCT07036172 1 trial
RAY1225	Raynovent	GLP-1 / GIP	Phase 3	— No upcoming date in registry	Not yet researched	NCT06893016
All active trials in this area: NCT06254261 NCT06893016 NCT07362030
Nimacimabunreviewed	Skye Bioscience, Inc.	Not yet classified	Phase 2	20 Nov 2026soon Primary completion, Phase 2	Not yet researched	NCT06577090 1 trial
BGE-102	BioAge Labs	NLRP3 inhibitor	Phase 2	30 Nov 2026soon Primary completion, Phase 2	Public BIOA	NCT07656727 1 trial
BMB-101	Bright Minds Biosciences	5-HT2C agonist	Phase 2	Nov 2026soon Primary completion, Phase 2	Public DRUG	NCT07266324 1 trial
KBP-336	KeyBioscience	Dual amylin / calcitonin receptor agonist	Phase 2	Nov 2026soon Primary completion, Phase 2	Not yet researched	NCT06833749 1 trial
ZT006	QL Biopharm	Not yet classified	Phase 2	12 Dec 2026 Primary completion, Phase 2	Private	NCT07230132 1 trial
NNC0662-0419	Novo Nordisk	Not yet classified	Phase 2	14 Dec 2026 Primary completion, Phase 2	Public NVO	NCT07184632
All active trials in this area: NCT07184632 NCT07525791 NCT07639021
AZD9550	AstraZeneca	GLP-1 / glucagon	Phase 1/2	29 Jan 2027 Primary completion, Phase 1/2	Public AZN	NCT06151964
All active trials in this area: NCT06151964 NCT07013643 NCT07017179 NCT07911514
HM15275	Hanmi	GLP-1 / GIP / glucagon	Phase 2	Jan 2027 Primary completion, Phase 2	Public 128940.KS	NCT07205900 1 trial
KDS2010	NeuroBiogen	MAO-B inhibitor	Phase 2	31 Jan 2027 Primary completion, Phase 2	Not yet researched	NCT07009171 1 trial
NKS-3 modified linoleic acid	EktaH	Fat-taste receptor agonist (CD36 / GPR120)	Phase 2	5 Feb 2027 Primary completion, Phase 2	Not yet researched	NCT07882654 1 trial
MOTS-c	Hudson Biotech	Mitochondrial-derived peptide	Phase 2	14 Feb 2027 Primary completion, Phase 2	Not yet researched	NCT07505745 1 trial
RN3161	Ikaria Bioscience	Not yet classified	Phase 1/2	15 Feb 2027 Primary completion, Phase 1/2	Not yet researched	NCT07245771 1 trial
ARO-ALK7	Arrowhead	ALK7 siRNA	Phase 1/2	Feb 2027 Primary completion, Phase 1/2	Public ARWR	NCT06937203 1 trial
AT673	Antag Therapeutics	GIP receptor antagonist	Phase 2	Feb 2027 Primary completion, Phase 2	Private	NCT07724340 1 trial
(S)-pindolol benzoate	Actimed Therapeutics	Not yet classified	Phase 2	Mar 2027 Primary completion, Phase 2	Not yet researched	NCT07101939 1 trial
ACCG-2671	Aconcagua Bio	Not yet classified	Phase 1/2	Mar 2027 Primary completion, Phase 1/2	Not yet researched	NCT07815678 1 trial
HRS-4729	Hengrui	Not yet classified	Phase 2	Mar 2027 Primary completion, Phase 2	Public 600276.SS	NCT07690826
All active trials in this area: NCT07690826 NCT07807059
macupatide	Eli Lilly	Not yet classified	Phase 2	Mar 2027 Primary completion, Phase 2	Public LLY	NCT07215559
All active trials in this area: NCT07215559 NCT07589608 NCT07765511
ALN-2232	Alnylam	siRNA, target not disclosed	Phase 1/2	28 Apr 2027 Primary completion, Phase 1/2	Public ALNY	NCT07463846 1 trial
GL0034	Sun Pharma	Long-acting GLP-1	Phase 2	Apr 2027 Primary completion, Phase 2	Public SUNPHARMA.NS	NCT07282743 1 trial
RM-718	Rhythm	MC4R agonist	Phase 1/2	7 May 2027 Primary completion, Phase 1/2	Public RYTM	NCT06239116 1 trial
ERX1000	ERX Pharmaceuticals	Not yet classified	Phase 2	May 2027 Primary completion, Phase 2	Not yet researched	NCT07570758 1 trial
LY3457263	Eli Lilly	Not yet classified	Phase 2	May 2027 Primary completion, Phase 2	Public LLY	NCT06897475 1 trial
S1B-509	S1 Biopharma	Not yet classified	Phase 2	15 Jun 2027 Primary completion, Phase 2	Not yet researched	NCT06517797 1 trial
BI 3034701	Boehringer Ingelheim	Not yet classified	Phase 2	26 Jun 2027 Primary completion, Phase 2	Private	NCT07662122
All active trials in this area: NCT07662122 NCT07693231 NCT07754474
BIO101 20-hydroxyecdysone	Biophytis	MAS receptor activator	Phase 2	Jun 2027 Primary completion, Phase 2	Not yet researched	NCT07411378 1 trial
CSTI-500	ConSynance Therapeutics	Not yet classified	Phase 2	Jun 2027 Primary completion, Phase 2	Not yet researched	NCT07348601 1 trial
BGM1812	BrightGene	Not yet classified	Phase 2	1 Aug 2027 Primary completion, Phase 2	Not yet researched	NCT07918625
All active trials in this area: NCT07224399 NCT07918625
PF-08653945	Pfizer	Not yet classified	Phase 2	4 Aug 2027 Primary completion, Phase 2	Public PFE	NCT07575932
All active trials in this area: NCT07575932 NCT07725809
NA-931	Biomed Industries	Multi-receptor agonist incl. GLP-1	Phase 2	15 Aug 2027 Primary completion, Phase 2	Not yet researched	NCT06732245 1 trial
ALV-100	Alveus Therapeutics	Not yet classified	Phase 2	24 Aug 2027 Primary completion, Phase 2	Not yet researched	NCT07837973
All active trials in this area: NCT07399678 NCT07837973
ALN-4324	Alnylam	siRNA, target not disclosed	Phase 1/2	31 Aug 2027 Primary completion, Phase 1/2	Public ALNY	NCT06845202 1 trial
SYH2069	CSPC	Not yet classified	Phase 2	30 Sep 2027 Primary completion, Phase 2	Public 1093.HK	NCT07803991
All active trials in this area: NCT07736391 NCT07803991
LY3532226	Eli Lilly	Not yet classified	Phase 2	Sep 2027 Primary completion, Phase 2	Public LLY	NCT06143956 1 trial
LY3549492	Eli Lilly	Not yet classified	Phase 2	Sep 2027 Primary completion, Phase 2	Public LLY	NCT06143956 1 trial
ARO-INHBE	Arrowhead	INHBE siRNA	Phase 1/2	15 Oct 2027 Primary completion, Phase 1/2	Public ARWR	NCT06700538 1 trial
enobosarm	Veru	SARM, muscle preservation	Phase 2	Oct 2027 Primary completion, Phase 2	Public VERU	NCT07446998 1 trial
SRSD384	Sirius Therapeutics	siRNA	Phase 1/2	Oct 2027 Primary completion, Phase 1/2	Not yet researched	NCT07557355 1 trial
WVE-007	Wave Life Sciences	INHBE siRNA	Phase 1/2	Dec 2027 Primary completion, Phase 1/2	Public WVE	NCT06842186 1 trial
LY4086940	Eli Lilly	Not yet classified	Phase 2	Jan 2028 Primary completion, Phase 2	Public LLY	NCT07890376 1 trial
LUM-201 ibutamoren	Lumos Pharma	Oral growth hormone secretagogue	Phase 2	15 Feb 2028 Primary completion, Phase 2	Not yet researched	NCT07754045 1 trial
TE-8105	Immunwork	Not yet classified	Phase 2	Feb 2028 Primary completion, Phase 2	Not yet researched	NCT07857473 1 trial
ABBV-295	AbbVie	Not yet classified	Phase 2	Mar 2028 Primary completion, Phase 2	Public ABBV	NCT07752979
All active trials in this area: NCT07291232 NCT07514260 NCT07752979
bivamelagon	Rhythm	Oral MC4R agonist	Phase 2	15 Apr 2028 Primary completion, Phase 2	Public RYTM	NCT07156578 1 trial
GUB-UCN2	Gubra	Urocortin-2 (CRF2 agonist)	Phase 1/2	Dec 2028 Primary completion, Phase 1/2	Public GUBRA.CO	NCT07702890 1 trial
HS235unreviewed	35Pharma Inc., a GSK company	Not yet classified	Phase 1/2	Jan 2029 Primary completion, Phase 1/2	Not yet researched	NCT07123779 1 trial
APH-012 APHD-012 · APHP-012 · APHD-002 · APHP-002	Aphaia Pharma	Not yet classified	Phase 2	— No upcoming date in registry	Not yet researched	NCT07008456 1 trial
bimagrumab BYM338	Eli Lilly	Activin type II receptor antibody	Phase 2	— No upcoming date in registry	Public LLY	NCT06643728 1 trial
bremelanotide Vyleesi	Palatin	MC4R agonist	Phase 2 US-approved for another use	— No upcoming date in registry	Public PTN	NCT06565611 1 trial
ECC4703	Eccogene	THR-beta agonist	Phase 2	— No upcoming date in registry	Not yet researched	NCT07505303 1 trial
EMP16 EMP16-02	Empros Pharma	Orlistat + acarbose, fixed dose	Phase 2	— No upcoming date in registry	Not yet researched	NCT06993428 1 trial
garetosmab	Regeneron	Activin A antibody	Phase 2	— No upcoming date in registry	Public REGN	NCT06299098 1 trial
IMM01-STEMunreviewed	Immunis, Inc.	Not yet classified	Phase 2	— No upcoming date in registry	Not yet researched	NCT06600581 1 trial
MKP10241	Mankind Pharma	Not yet classified	Phase 2	— No upcoming date in registry	Public MANKIND.NS	NCT07098663 1 trial
RO7204239	Roche	Anti-myostatin antibody	Phase 2	— No upcoming date in registry	Public ROG.SW	NCT06965413
All active trials in this area: NCT06965413 NCT07137585
taldefgrobep alfa	Biohaven	Anti-myostatin adnectin	Phase 2	— No upcoming date in registry	Public BHVN	NCT07281495 1 trial
THDBH120	Tonghua Dongbao	GLP-1 / GIP	Phase 2	— No upcoming date in registry	Public 600867.SS	NCT07036601 1 trial
trevogrumab	Regeneron	Myostatin antibody	Phase 2	— No upcoming date in registry	Public REGN	NCT06299098 1 trial
VCT220	Vincentage Pharma	Oral small-molecule GLP-1	Phase 2	— No upcoming date in registry	Not yet researched	NCT07360275 1 trial

Showing 96 of 96 programs. Sorted by phase, then next catalyst.Orange dot: alias or mechanism not yet confirmed. news from a press report, not the registry. unreviewed grouped automatically.

Ask Claude about this landscape. Connect once, then ask in plain English.
Which oral GLP-1s read out in the next six months?

Connect to Claude

Want a landscape of your area?

Tell us the disease, target or modality. We build the first ones by hand and email you the link, free during November.

Need it hand-checked in 48 hours? A custom landscape is $250.